XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Non-Redeemable Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Shares [Member]
Beginning balance at Jan. 29, 2022 $ 602,468 $ 827 $ 14,256 $ 291,444 $ 350,206 $ (36,408) $ (17,857)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income (Loss) 71,915       71,915    
Other comprehensive income (loss) (4,803)         (4,803)  
Share-based compensation expense 14,017     14,017      
Restricted stock issuance 0   316 (316)      
Restricted shares withheld for taxes (3,942)   (73) 73 (3,942)    
Shares repurchased (72,689)   (1,380)   (71,309)    
Other 0 (12) (30) 42      
Ending balance at Jan. 28, 2023 606,966 815 13,089 305,260 346,870 (41,211) (17,857)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income (Loss) (16,827)       (16,827)    
Other comprehensive income (loss) 1,587         1,587  
Share-based compensation expense 14,014     14,014      
Restricted stock issuance 0   296 (296)      
Restricted shares withheld for taxes (2,249)   (86) 86 (2,249)    
Shares repurchased (32,027)   (1,261)   (30,766)    
Excise taxes related to repurchases of common stock (262)       (262)    
Other 0 (2) (77) 79      
Ending balance at Feb. 03, 2024 571,202 813 11,961 319,143 296,766 (39,624) (17,857)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income (Loss) (18,890)       (18,890)    
Other comprehensive income (loss) (5,800)         (5,800)  
Share-based compensation expense 12,866     12,866      
Restricted stock issuance 0   338 (338)      
Restricted shares withheld for taxes (2,572)   (90) 90 (2,572)    
Shares repurchased (9,789)   (400)   (9,389)    
Excise taxes related to repurchases of common stock (28)       (28)    
Other (19) 22 (36) (5)   0  
Ending balance at Feb. 01, 2025 $ 546,970 $ 835 $ 11,773 $ 331,756 $ 265,887 $ (45,424) $ (17,857)